In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Avenue Therapeutics Inc (NASDAQ: ATXI), with a price target of $11. The company’s shares opened today at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.2% and a 40.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
Avenue Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATXI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avenue Therapeutics, Inc. operates as a pharmaceutical company. It engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. The company was founded on February 9, 2015 and is headquartered in New York, NY.
